Evaluation of IMIDs (“immunomodulatory drugs” a term often used for thalidomide derivatives) as so-called “molecular glue”, compounds that act monovalently by inducing or facilitating degradation of a target protein, gained specific interest after they were shown to degrade Ikaros (IKZF1) and Aiolos (IKZF3) [7,8] and demonstrated promise for the treatment of multiple myeloma. This evidence concerns the gene IKZF1 and plasma cell myeloma.